Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
An extremely rare adenocarcinoma that arises from the fallopian tube. It is characterized by the presence of neoplastic epithelial cells that contain intracytoplasmic mucin. The cases that have been reported are predominantly in situ mucinous adenocarcinomas.
6 clinical trials registered. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 2 PHASE3, 1 PHASE2, 2 PHASE1. Research is primarily sponsored by academic and government institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT04739800](https://clinicaltrials.gov/study/NCT04739800) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 12:28 PM UTC
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents |
PHASE2 |
National Cancer Institute (NCI) |
ACTIVE_NOT_RECRUITING |
[NCT01167712](https://clinicaltrials.gov/study/NCT01167712) | Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer | PHASE3 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT04092270](https://clinicaltrials.gov/study/NCT04092270) | A Study Combining the Peposertib (M3814) Pill With Standard Chemotherapy in Patients With Ovarian Cancer With an Expansion in High Grade Serous Ovarian Cancer and Low Grade Serous Ovarian Cancer | PHASE1 | National Cancer Institute (NCI) | ACTIVE_NOT_RECRUITING |
[NCT02068794](https://clinicaltrials.gov/study/NCT02068794) | MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer | PHASE1 | Mayo Clinic | ACTIVE_NOT_RECRUITING |
[NCT05415709](https://clinicaltrials.gov/study/NCT05415709) | Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer | EARLY_PHASE1 | Ohio State University Comprehensive Cancer Center | ACTIVE_NOT_RECRUITING |
10 publications have been identified in PubMed for fallopian tube mucinous adenocarcinoma. Research spans Case Report / Case Series (50%), Basic Science / Preclinical (20%), and Epidemiology / Natural History (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 5 | 50% |
Laboratory research | 2 | 20% |
Disease patterns and progression | 2 | 20% |
Research summaries | 1 | 10% |
Gatta G (2025). [PMID: 40180806](https://pubmed.ncbi.nlm.nih.gov/40180806/). *European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology*. [Case Report / Case Series]
Li L (2025). [PMID: 40760340](https://pubmed.ncbi.nlm.nih.gov/40760340/). *The journal of pathology. Clinical research*. [Basic Science / Preclinical]
Keretić D (2025). [PMID: 41010589](https://pubmed.ncbi.nlm.nih.gov/41010589/). *Journal of clinical medicine*. [Case Report / Case Series]
Yuan M (2025). [PMID: 39992437](https://pubmed.ncbi.nlm.nih.gov/39992437/). *Virchows Archiv : an international journal of pathology*. [Case Report / Case Series]
Zhou Y (2024). [PMID: 38937781](https://pubmed.ncbi.nlm.nih.gov/38937781/). *BMC women's health*. [Case Report / Case Series]
Wong RW (2024). [PMID: 38477341](https://pubmed.ncbi.nlm.nih.gov/38477341/). *Histopathology*. [Epidemiology / Natural History]
Wang C (2024). [PMID: 39809200](https://pubmed.ncbi.nlm.nih.gov/39809200/). *Medicine*. [Basic Science / Preclinical]
Lu LH (2024). [PMID: 39077828](https://pubmed.ncbi.nlm.nih.gov/39077828/). *Zhonghua zhong liu za zhi [Chinese journal of oncology]*. [Epidemiology / Natural History]
Sumtsov D (2024). [PMID: 38015299](https://pubmed.ncbi.nlm.nih.gov/38015299/). *Wiener medizinische Wochenschrift (1946)*. [Review / Meta-Analysis]
Zhang LL (2024). [PMID: 38825898](https://pubmed.ncbi.nlm.nih.gov/38825898/). *Zhonghua bing li xue za zhi = Chinese journal of pathology*. [Case Report / Case Series]